[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

10:00am, Saturday, 30'th May 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) prov

If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

10:23am, Thursday, 28'th May 2026

When Wall Street's growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles.

Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

03:00am, Thursday, 28'th May 2026

Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

04:05pm, Wednesday, 27'th May 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies

Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative

10:00am, Wednesday, 27'th May 2026

CHEVY CHASE, Md.--(BUSINESS WIRE)-- #Biotech--Caring Men Global, a nonprofit dedicated to supporting male caregivers facing a loved one's cancer, has received a grant from Exelixis to launch “Strong

Exelixis: Financial Performance Improves Faster Than Market Expectations

05:26pm, Saturday, 23'rd May 2026

Exelixis remains undervalued despite a 13%+ rally post-Q1, supported by robust double-digit growth, sector-leading profitability, and strong free cash flow. Q1 revenue grew 10% year-over-year, driven

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

05:04am, Saturday, 23'rd May 2026

Exelixis NASDAQ: EXEL remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company's senior vice president

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

05:00pm, Thursday, 21'st May 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanza

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

04:00pm, Wednesday, 20'th May 2026

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study

03:35pm, Wednesday, 20'th May 2026

Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.

Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

11:00am, Tuesday, 19'th May 2026

Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by